Patents by Inventor Barbara S. Slusher

Barbara S. Slusher has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pharmaceutical compositions and methods of treating a glutamate abnormality and effecting a neuronal activity in an animal using NAALADase inhibitors
    Patent number: 6017903
    Abstract: The present invention relates to a method of treating a glutamate abnormality and a method of effecting a neuronal activity in an animal using a NAALADase inhibitor, and a pharmaceutical composition comprising an effective amount of a NAALADase inhibitor for treating a glutamate abnormality and effecting a neuronal activity in an animal.
    Type: Grant
    Filed: June 27, 1997
    Date of Patent: January 25, 2000
    Assignee: Guilford Pharmaceuticals Inc.
    Inventors: Barbara S. Slusher, Paul F. Jackson, Kevin L. Tays, Keith M. Maclin
  • Methods of cancer treatment using naaladase inhibitors
    Patent number: 6011021
    Abstract: The present disclosure relates to dipeptidase inhibitors, and more particularly, to novel methods of using phosphonate derivatives, hydroxyphosphinyl derivatives, and phosphoramidate derivatives to inhibit N-Acetylated .alpha.-Linked Acidic Dipeptidase (NAALADase) enzyme activity, and to treat prostate diseases, especially using the compounds of the present invention for the inhibition of the growth of prostate cancer cells.
    Type: Grant
    Filed: May 28, 1997
    Date of Patent: January 4, 2000
    Assignee: Guilford Pharmaceuticals Inc.
    Inventors: Barbara S. Slusher, Paul F. Jackson, Kevin L. Tays, Keith M. Maclin
  • Treatment of global and focal ischemia using naaladase inhibitors
    Patent number: 6004946
    Abstract: The present invention includes compositions and methods of treatment for glutamate abnormalities and associated nervous tissue insult in a animal by inhibition of NAALADase enzyme. Compositions include glutamate-derived hydroxyphosphinyl derivative compounds, acidic peptide analogs, phosphinic acid derivatives and mixtures thereof that inhibit NAALADase enzyme activity and their use for treating glutamate abnormalities such as created by global and focal ischemia.
    Type: Grant
    Filed: July 8, 1997
    Date of Patent: December 21, 1999
    Assignee: Guilford Pharmaceuticals Inc.
    Inventors: Barbara S. Slusher, Paul F. Jackson
  • Treatment of global and focal ischemia using NAALADase inhibitors
    Patent number: 5985855
    Abstract: The present invention includes compositions and methods of treatment for glutamate abnormalities and associated nervous tissue insult in a animal by inhibition of NAALADase enzyme. Compositions include glutamate-derived hydroxyphosphinyl derivative compounds, acidic peptide analogs, phosphinic acid derivatives and mixtures thereof that inhibit NAALADase enzyme activity and their use for treating glutamate abnormalities such as created by global and focal ischemia.
    Type: Grant
    Filed: November 20, 1997
    Date of Patent: November 16, 1999
    Assignee: Guilford Pharmaceuticals Inc.
    Inventors: Barbara S. Slusher, Paul F. Jackson
  • Use of NAALADase activity to identify prostate cancer and benign prostatic hyperplasia
    Patent number: 5981209
    Abstract: The present invention relates to novel methods and kits for quantitating N-Acetylated .alpha.-Linked Acidic Dipeptidase (NAALADase) enzyme activity in biological samples, including prostate biopsies, seminal fluid, ejaculate, prostatic fluid, blood, saliva, and urine, for the purpose of identifying and differentiating between prostate carcinoma, benign prostatic hyperplasia, and normal prostate.
    Type: Grant
    Filed: December 4, 1997
    Date of Patent: November 9, 1999
    Assignee: Guilford Pharmaceuticals Inc.
    Inventors: Barbara S. Slusher, Rena S. Lapidus
  • Pharmaceutical compositions and methods of treating compulsive disorders using NAALADase inhibitors
    Patent number: 5977090
    Abstract: The present invention relates to a pharmaceutical composition and a method for treating a compulsive disorder using a NAALADase inhibitor.
    Type: Grant
    Filed: July 23, 1997
    Date of Patent: November 2, 1999
    Assignee: Guilford Pharmaceuticals Inc.
    Inventors: Barbara S. Slusher, Paul F. Jackson, Kevin L. Tays, Keith M. Maclin
  • Naaladase inhibitors
    Patent number: 5968915
    Abstract: The present disclosure relates to dipeptidase inhibitors, and more particularly, to N-Acetylated .alpha.-Linked Acidic Dipeptidase (NAALADase) enzyme inhibitors which are proposed as novel agents for the treatment of prostate cancer. NAALADase is enzyme which is a membrane-bound metalloprotease which hydrolyzes the dipeptide, N-acetyl-L-aspartate-L-glutamate (NAAG) to yield glutamate and N-acetylaspartate. The compounds of the present invention include phosphinic acid derivatives that inhibit NAALADase enzyme activity and which have been found useful for inhibiting the growth of prostate cancer cells.
    Type: Grant
    Filed: April 8, 1997
    Date of Patent: October 19, 1999
    Assignee: Guilford Pharmaceuticals Inc.
    Inventors: Paul F. Jackson, Barbara S. Slusher
  • Hydroxamic acid derivatives
    Patent number: 5962521
    Abstract: The present invention relates to hydroxamic acid derivatives that inhibit N-Acetylated .alpha.-Linked Acidic Dipeptidase (NAALADase) enzyme activity, pharmaceutical compositions comprising such derivatives, and methods of using such derivatives to inhibit NAALADase activity, to treat a glutamate abnormality and to treat a prostate disease in an animal.
    Type: Grant
    Filed: April 4, 1997
    Date of Patent: October 5, 1999
    Assignee: Guilford Pharmaceuticals Inc.
    Inventors: Paul F. Jackson, Kevin L. Tays, Keith M. Maclin, Barbara S. Slusher
  • Pharmaceutical compositions and methods for treating compulsive disorders using pyrrolidine derivatives
    Patent number: 5925666
    Abstract: The present invention relates to pharmaceutical compositions and methods for treating compulsive disorders using pyrrolidine derivatives.
    Type: Grant
    Filed: July 21, 1997
    Date of Patent: July 20, 1999
    Assignee: Guilford Pharmaceuticals Inc.
    Inventors: Paul F. Jackson, Barbara S. Slusher
  • Certain sulfoxide and sulfone derivatives
    Patent number: 5902817
    Abstract: The present invention relates to thio derivatives that inhibit N-Acetylated .alpha.-Linked Acidic Dipeptidase (NAALADase) enzyme activity, pharmaceutical compositions comprising such derivatives, and methods of using such derivatives to inhibit NAALADase activity, to treat a glutamate abnormality and to treat a prostate disease in an animal.
    Type: Grant
    Filed: April 9, 1997
    Date of Patent: May 11, 1999
    Assignee: Guilford Pharmaceuticals Inc.
    Inventors: Paul F. Jackson, Kevin L. Tays, Keith M. Maclin, Barbara S. Slusher
  • Naaladase inhibitors
    Patent number: 5880112
    Abstract: The present disclosure relates to dipeptidase inhibitors, and more particularly, to N-Acetylated .alpha.-Linked Acidic Dipeptidase (NAALADase) enzyme inhibitors which are proposed as novel agents for the treatment of prostate cancer. NAALADase is enzyme which is a membrane-bound metalloprotease which hydrolyzes the dipeptide, N-acetyl-L-aspartate-L-glutamate (NAAG) to yield glutamate and N-acetylaspartate. The compounds of the present invention include phosphinic acid derivatives that inhibit NAALADase enzyme activity and which have been found useful for inhibiting the growth of prostate cancer cells.
    Type: Grant
    Filed: April 8, 1997
    Date of Patent: March 9, 1999
    Assignee: Guilford Pharmaceuticals Inc.
    Inventors: Paul F. Jackson, Barbara S. Slusher
  • Phosphoramidate derivatives
    Patent number: 5863536
    Abstract: The present invention includes phosphoramidate derivatives, compositions containing the same, and methods of using them as NAALADase inhibitors, particularly for the treatment of glutamate abnormalities and associated nervous tissue insult in a animal and for treatment of prostate disease and prostate cancer by inhibition of NAALADase enzyme.
    Type: Grant
    Filed: December 31, 1996
    Date of Patent: January 26, 1999
    Assignee: Guilford Pharmaceuticals Inc.
    Inventors: Paul F. Jackson, Barbara S. Slusher, Kevin L. Tays, Keith M. Maclin
  • Treatment of global and focal ischemia using naaladase inhibitors
    Patent number: 5824662
    Abstract: The present invention includes compositions and methods of treatment for glutamate abnormalities and associated nervous tissue insult in a animal by inhibition of NAALADase enzyme. Compositions include glutamate-derived hydroxyphosphinyl derivative compounds, acidic peptide analogs, phosphinic acid derivatives and mixtures thereof that inhibit NAALADase enzyme activity and their use for treating glutamate abnormalities such as created by global and focal ischemia.
    Type: Grant
    Filed: September 27, 1996
    Date of Patent: October 20, 1998
    Assignee: Guilford Pharmaceuticals Inc.
    Inventors: Barbara S. Slusher, Paul F. Jackson
  • Methods of cancer treatment using naaladase inhibitors
    Patent number: 5804602
    Abstract: The present invention is based upon the surprising discovery that NAALADase inhibitors exhibit a significant inhibitory effect on the growth of prostate cancer cells. The present disclosure relates to methods of treating diseases of the prostate, in particular prostate cancer, using novel compositions which inhibit N-Acetylated .alpha.-Linked Acidic Dipeptidase (NAALADase) enzyme activity in humans and warm-blooded animals. Furthermore, as NAALADase has been found in other tissues of the body it may serve as a cancer associated protein and thus NAALADase inhibitors would be expected to show efficacy in the treatment of other forms of cancer.
    Type: Grant
    Filed: June 17, 1996
    Date of Patent: September 8, 1998
    Assignee: Guilford Pharmaceuticals Inc.
    Inventors: Barbara S. Slusher, Paul F. Jackson
  • Inhibitors of NAALADase enzyme activity
    Patent number: 5795877
    Abstract: The present invention includes compounds, compositions, and methods of treatment for glutamate abnormalities and associated nervous tissue insult in a animal by inhibition of NAALADase enzyme. Compositions include phosphonate derivatives and mixtures thereof that inhibit NAALADase enzyme activity and their use for treating glutamate abnormalities such as created by global and focal ischemia and for treatment of prostate disease and prostate cancer by inhibition of NAALADase enzyme.
    Type: Grant
    Filed: December 31, 1996
    Date of Patent: August 18, 1998
    Assignee: Guilford Pharmaceuticals Inc.
    Inventors: Paul F. Jackson, Barbara S. Slusher, Kevin L. Tays, Keith M. Maclin
  • Certain phosphonomethyl-pentanedioic acid derivatives thereof
    Patent number: 5672592
    Abstract: The present disclosure relates to dipeptidase inhibitors, and more particularly, to N-Acetylated .alpha.-Linked Acidic Dipeptidase (NAALADase) enzyme inhibitors which are proposed as novel agents for the treatment of prostate cancer. NAALADase is enzyme which is a membrane-bound metalloprotease which hydrolyzes the dipeptide, N-acetyl-L-aspartate-L-glutamate (NAAG) to yield glutamate and N-acetylaspartate. The compounds of the present invention include phosphinic acid derivatives that inhibit NAALADase enzyme activity and which have been found useful for inhibiting the growth of prostate cancer cells.
    Type: Grant
    Filed: June 17, 1996
    Date of Patent: September 30, 1997
    Assignee: Guilford Pharmaceuticals Inc.
    Inventors: Paul F. Jackson, Barbara S. Slusher